← back to picks

Founded 1995 · IPO 2014 · HQ Rotterdam, NLReporting EUR (IFRS)Credit A3/A- · net debt/EBITDA 2.8×Valuation 2026-05-24MC 1000-iter · 4 axes (council-revised)Council REVISED DOWN margin · S/C · governance Damodaran FCFF · Dark

Deeply overvalued · -65.8% margin of safety

Market sits above MC p95 ceiling

Council-revised DCF lands at €57.84/sh vs €95.88 Euronext Amsterdam — a -65.8% margin of safety with 100.0% of Monte Carlo paths printing below market. Three council reviewers cut target margin to 7.75% (Brenntag peer, not Retail Distributors median), sales/capital to 1.5 in Y6-10 (€2.61B goodwill is not capital-light), and governance to 8% (CEO/CFO churn + first-since-IPO dividend cut reads as management reacting). JPM Underweight is the central call.

            MC fan p5-p95 (EUR/share, after 8% governance haircut); market
            €95.88 sits
            22% ABOVE the p95 ceiling →
            100% of iterations have intrinsic
            < market.
          

Sector Specialty chem distribution · Retail DistributorsGeo US 18.5% / DE 11% / CN 9% / UK 6% / FR 5%MC σ ±€13.25 · p5 €35 / p95 €79Governance Diffuse free float · CEO/CFO churn · 8% haircutQuality A3/A- synth · ROIIC 3Y −5.97% (Alpha Spread)Council REVISED margin · S/C · governance (DOWN)

Intrinsic / share

€57.84

post 8% gov · council-revised

Market / share

€95.88

Euronext Amsterdam · IMCD.AS

Margin of safety

-65.8%

vs intrinsic

Enterprise value

€5.29B

86.4% terminal

Cost of equity / debt

7.72% / 2.45%

β 0.989 · CRP 1.15%

Terminal ROIC / g

8.68% / 2.50%

spread ~222bp · narrow vs pre-council 440bp

What it sells, where it sells

Operating segments

Coatings & ConstructionIndustrial cyclical exposure — JPM cited Q2-Q3 26 ME supply boost fading into 27~30%

Pharma SolutionsHigher-GP mix · destocking largely cleared · principal anchor of bull-case margin recovery~22%

Beauty & Personal CareDefensive consumer end-market · higher conversion margin than industrial~18%

Food & Nutrition + Industrial OtherDefensive mix (food) + lubricants / advanced materials / industrial chemicals~30%

IMCD reports a single Distribution segment; the customer-end-market split above is reconstructed from FY2025 AR narrative and the digest. JPM Underweight rests on the principal-agent exclusivity question across the full customer book — not specific to any one end-market.

Country mix (revenue-weighted CRP input)

🇺🇸United States18.5%

🇩🇪Germany11.0%

🇨🇳China9.0%

🇬🇧United Kingdom6.0%

🇫🇷France5.0%

🇧🇷Brazil5.0%

🇮🇹Italy4.0%

🇮🇳India4.0%

🇯🇵Japan3.0%

🇦🇺Australia3.0%

🌐35 other countries38.2%

Revenue-only weighting (distribution model: cash follows end-customer, not supplier). EMEA 42% · APAC 26% · NA 20% · LatAm 11%. Weighted CRP 1.15% — material EM tail (China + India + Brazil = 18%) keeps CRP off the floor.

Quality profile & the two-sided argument

A five-axis read on the DCF's load-bearing assumptions, plus the bull-vs-bear case distilled into anchor bullets.

Quality snowflake (each axis 0–6)

Growth3/6Rev €5.14B→€9.06B (~6.5% CAGR); council slowed M&A flywheel below historical 11.9%

Margin2/6Y10 7.75% (council-cut from 8.5%); FY22 peak 10% but FY25 prints 7.5% — three-year compression

Capital eff2/6S/C 1.4→1.5 (council-cut from 1.7/1.8); €2.61B goodwill base is not capital-light

Balance sheet3/6A3/A- synth, ND/EBITDA 2.8x; first-since-IPO ABB Nov 24 + FY25 dividend cut

Governance2/6Diffuse free float but two CEO changes in 3y + CFO succession for 2027 + 11.49% short interest

The two-sided case

Bull case anchors (live in MC right tail)

Margin recovery to 8.5%+ EBIT. Pharma/food destocking cleared (Q1 26 PR); mix shift to life-sciences holds; FY22 peak 10% EBIT shows the franchise can print there.
M&A flywheel real — 100+ deals integrated since 1995. Dong Yang FT (KR) + Willows (IE) closed Q1 26; bolt-on cadence intact at ~10-12/yr small deals.
Q1 26 FCF +19% to €121M. Cash conversion strengthening as WC build unwinds — operating engine functioning even with EBITA down 2% CFX.
Insider net buying near cycle low. Kooijmans bought €81K at €81.71 in Nov 25 — most notable signal; three director purchases TTM, zero sales.
Even MC p95 (€79) is still -18% BELOW market. The bull-case PT exists in this distribution and it still says SELL.

Bear case anchors (council-revised base)

JPM Chinese-disintermediation thesis. Apr-May 26 UW: structural pressure on distributors if Chinese specialty producers stop signing exclusive supply agreements. The moat IS exclusivity.
3Y ROIIC −5.97% (Alpha Spread). Marginal acquisitions deploying capital BELOW cost; Q1 26 PR concedes "recently acquired companies had lower GP margins than IMCD."
CEO/CFO churn + dividend cut + dilutive ABB. Founder→Diele-Braun (18mo)→Jordan; CFO succession announced Dec 25 for 2027; FY25 first dividend cut since IPO; €300M Nov 24 ABB at non-peak.
Margin compressing 3y straight. FY22 10.0% → FY23 9.6% → FY24 9.2% → FY25 7.8% EBIT. Council base bakes 7.75%, NOT 8.5% — Brenntag Specialties peer is the honest anchor, not Retail Distributors median 10.1%.
11.49% short interest (~€640M). Arrowstreet + JPM AM + BlackRock + PDT + CFM + Citadel + Two Sigma — multi-quant AND multi-fundamental conviction setup. Unusual for a "quality compounder".

Thesis & open questions

Investment thesis

Council-revised intrinsic €57.84/sh vs €95.88 Euronext close — 65.8% OVERVALUED. Three council reviewers independently pulled target_op_margin from 8.5% to 7.75% (Brenntag Specialties peer, not Retail Distributors median), sales_to_capital_y6_10 from 1.8 to 1.5 (€2.61B goodwill is not capital-light), and governance_discount from 5% to 8% (CEO/CFO churn pattern reads as management reacting, not steering).
P(intrinsic < market) = 100% across 1000 MC iterations sampling rev growth, margin, terminal_g, and governance. Every single iteration — even the MC p95 €79 bull case — prints BELOW the €95.88 market. The distribution and the market have NO overlap.
Margin debate is the load-bearing assumption. Council's 7.75% sits half-way between today's 7.5% TTM trough and the FY22 peak 10% EBIT. The pre-council 8.5% assumed "muddle-through recovery without proof." Mid-cycle compression is still working through — claim 4 in the narrative explicitly extends year-of-convergence from 5 to 7.
MC mean €56.48 ± €13.25/sh. The distribution centres €39 BELOW market with a tight σ; market would need to fall ~41% to reach MC mean or rise off the SELL band entirely.
The Alpha Spread −5.97% 3Y ROIIC is a real signal. Buy-and-build platforms can mask compression with M&A-driven top-line, but the marginal acquisitions are demonstrably deploying capital below cost. Goodwill grew €2.6B (vs €2.2B prior year) without the ROC recovery to validate it.
JPM short thesis is too coherent to dismiss as noise. 11.49% short interest, Morgan Stanley downgrade to EW (€139→€100), Kempen downgrade to Neutral. Multiple fundamental shorts on a "quality compounder" is the screen.

Key debates (where the model can fail)

Q: Why 7.75% target margin, not the pre-council 8.5%?

A: Council won 7.75%. Brenntag Specialties FY25 EBITA prints ~9-10% — equivalent to ~7.0-7.5% EBIT once D&A is honest. "Retail Distributors" (Grainger/Fastenal) is wrong comp anchor — IMCD is principal-agent on behalf of suppliers, not MRO catalog. At 8.5% the SELL signal would be marginal; at 7.75% it's decisive.

Q: Is the JPM Chinese-disintermediation thesis already priced?

A: Council bands say no. MC margin downside extended to 6.0% (commodity-distribution take-rate) so the distribution has non-zero mass on the thesis materialising. Even that left tail produces a SELL — at €35 (MC p5) the model still says intrinsic is 60%+ below market.

Q: Diagnostic — terminal_growth 2.5% vs EUR rf 2.4%, breach?

A: 10bp soft-breach, does not move verdict. narrative.md anticipated this: orchestrator was instructed to rerun with g = rf − 25bp if EUR rf prints below 2.5%. Re-running with g = 2.15% would shave ~5-7% off intrinsic — the model is already SELL with €38 of margin against the bear case.

Q: Insider net buying is genuinely bullish — why discount it?

A: Real signal, but smaller stakes than the model error bars. Three director purchases totalling ~€231K is a positive but tiny relative to €640M short interest. Kooijmans Nov 25 buy at €81.71 was 15% below current €95.88 — even insiders bought BELOW where the market sits today.

Q: Could the bull-case (8.5%+ EBIT, M&A reaccelerates) save it?

A: It's in MC p95 €79 — still -18% below market. Even the right-tail iteration where margin recovers AND M&A flywheel restarts AND governance haircut compresses to 4% does not bridge the €17/sh gap. The bull case isn't the question — even the bull case says SELL.

Assumptions & provenance

Every input shown against its industry benchmark with a one-line rationale. This is what the DCF is actually built on.

Input	Our value	Benchmark	Δ	Rationale
Year-10 revenue	€8.8B	€7-9B Damodaran retail-distrib 5y projections	in-range	7.5% Y1-5 (organic 3-4% + M&A 4-5%) decaying to 3% by Y10. Historical 2014-25 CAGR 11.9% — we slow the platform by 540bp.
Year-10 EBIT margin	7.75%	10.1% Retail Distributors US median (62 firms)	−235 bp · COUNCIL	Council-revised DOWN from 8.5%. Brenntag Specialties FY25 ~9-10% EBITA (~7-7.5% EBIT) is the honest peer anchor; Retail Distributors comp is wrong (Grainger MRO ≠ principal-agent distribution). Sits half-way between FY25 7.5% trough and FY22 10% peak.
Sales-to-capital Y1-5	1.40	1.83 Retail Distributors US median	−43 bp · COUNCIL	Council-revised DOWN from 1.7. Goodwill drag persists in early years; €2.61B goodwill base vs €4.78B revenue makes "asset-light" partly fiction. Recent vintages must depreciate before sales/capital can recover.
Sales-to-capital Y6-10	1.50	1.83 Retail Distributors US median	−33 bp · COUNCIL	Council-revised DOWN from 1.8. Capped because single-fade can't represent moat-breaks scenario — keep capital base honest. Drives terminal ROC 8.7% (vs WACC 6.5% → spread 222bp), narrower margin than pre-council 11.4%.
Terminal growth	2.50%	2.40% EUR Bund 10y ceiling (Damodaran rule)	+10 bp · BREACH	Soft-breach of Damodaran ceiling. Engine diagnostic fired; narrative anticipates this case — rerun with g = rf − 25bp (2.15%) would shave ~5-7% off intrinsic. Verdict unchanged either way.
WACC	6.46%	EUR rf 2.40% + ERP 4.11% + weighted CRP 1.15%	auto-resolved	Engine derives from 45-country revenue-weighted CRP × Damodaran 2026 CRPs. EM tail (CN+IN+BR=18%) keeps weighted CRP off the floor at 1.15%.
Cost of debt (pre-tax)	3.29%	rf 2.40% + spread 89bp synthetic A3/A-	model-derived	Engine derives from interest coverage on €105M expense. ND/EBITDA 2.8x — upper end of IMCD's 2-3x historical band, supported by Sept 24 €500M IG bond + Nov 24 €300M ABB.
Governance haircut	8%	5% Step 2 default (clean float)	+300 bp · COUNCIL	Council-revised UP from 5%. Three reviewers independently flagged the original as treating diffuse ownership as the only consideration. CEO/CFO churn + first-since-IPO dividend cut + first-since-IPO ABB pattern reads as "management reacting, not steering." MC samples 4-18% to honour the unresolved transition.

Where the value could land

Bull / Base / Bear scenarios overlaid with the Monte Carlo distribution. Each band shows the PT range, with a tick marking the central PT.

Bear

€30-€40

-63%

JPM Chinese-disintermediation thesis materialises; take-rate compresses to commodity 6% EBIT; ROIIC stays sub-WACC; goodwill writedowns. Lives in MC p5 €27 tail.

P ≈ 25%

Base

€57.84

-65.8%

Council-revised inputs hold: margin to 7.75% by Y7, S/C 1.4/1.5, 8% gov; MC mean €56.48 brackets the DCF, p50 €56 confirms.

P ≈ 50%

Bull

€70-€90

-17%

Margin recovers to 9-10% EBIT + M&A reaccelerates with ROIIC restored; aligns with MC p95 €79. Even this still prints below €96 market.

P ≈ 25%

Probability-weighted PT: 0.25×€35.00 + 0.50×€57.84 + 0.25×€80.00 = €57.67/sh — -40% from €95.88. Even the BULL case PT €80 prints -17% from market — you are paid €16/share to be RIGHT on the bull case at current.

Risks to thesis (tail, not bear case)

Goodwill writedown forced by ROIIC continuationHigh

€2.61B goodwill carrying value vs €4.78B revenue; if 3Y ROIIC −5.97% (Alpha Spread) persists into Y3-5, auditor impairment test fails and the platform is forced to write down €0.5-1B. Hits book equity and reignites the cycle.

Take-private bid at current depressed priceHigh

No controlling shareholder, free float 98%, governance discount NOT zero. EQT / Cinven / Bain (former owner) could bid €110-120 — well below DCF €57.84 but a premium to €95.88 market — capping upside permanently at a bad price.

Multi-quant short crowding unwindsMed

11.49% short interest across 7 named institutions could squeeze on any positive catalyst (Q2 26 print, M&A news, China demand bounce). +15-20% price spike on a squeeze would not change intrinsic but would compound the SELL signal's drift.

FX strength: EUR rally vs USD/CNYMed

~60% non-EUR revenue (NA + APAC + LatAm). 10% EUR appreciation knocks reported EBIT another 100-150bps; FY26 reported margin could undershoot the council 7.75% target on FX alone.

New CEO does NOT reaccelerate M&AMed

Marcus Jordan (mid-2025) could declare M&A pause for 2026-27 to digest. Removes the historical 8-9% growth contribution; even council's 4-5% may be optimistic. Drops Y10 revenue €1B.

Diagnostic re-run lowers PT furtherMed

If terminal_growth drops from 2.5% to 2.15% (g = EUR rf − 25bp per Damodaran rule), intrinsic falls another 5-7% to ~€54. Verdict unchanged but margin of safety against the bear case widens.

10-year forecast

Revenue €5.14B → €9.06B over 10y (~6.5% CAGR — well below the 11.9% 2014-25 historical CAGR; M&A flywheel deliberately slowed). Operating margin ramps from base 7.50% to council-revised target 7.75% by Y7 (not Y5) — half-way between today's 7.5% TTM trough and the FY22 peak 10% EBIT, anchored on Brenntag Specialties peer not the Retail-Distributors median. FCFF climbs from €33M Y1 to €347M Y10 as reinvestment requirements compress.

Monte Carlo distribution

1000 iterations randomising revenue growth, target operating margin, terminal growth and governance discount (council-revised bands; correlations: rev×margin 0.40, margin×g 0.30). P(intrinsic < market €95.88) = 100.0% — every iteration in the distribution prints BELOW the €95.88 Euronext close.

Mean €56.48 ± €13.25/sh. Percentiles: p5 €34.82 · p25 €46.91 · p50 €56.45 · p75 €65.76 · p95 €78.64. Post council-revised 8% governance haircut already applied at the per-share level.

⚠ Active engine diagnostic — terminal_growth 2.50% > risk-free 2.40%. Damodaran's hard rule is g ≤ rf in perpetuity (perpetual growth above the safe rate implies infinite NPV). The breach is 10bp, inside reasonable tolerance, and narrative.md anticipated this case — if EUR rf prints below 2.5% the orchestrator was instructed to rerun with g = rf − 25bp (i.e., 2.15%). Re-running with g = 2.15% would shave roughly 5-7% off intrinsic (the model is already SELL); the diagnostic does not change the verdict.

Cost of capital build

Risk-free rate	2.40%
Mature-market ERP	4.11%
Levered β	0.989
Weighted CRP	1.15%
Cost of equity	7.72%
Pre-tax cost of debt (synth A3/A-)	2.45%
D / V	~29%
WACC	6.46%

Full year-by-year DCF

Year	Revenue	Op mgn	EBIT	EBIT(1−t)	Reinvest	FCFF	PV
Y1	€5.14B	7.54%	€388M	€290M	€256M	€33M	€31M
Y2	€5.53B	7.57%	€419M	€313M	€276M	€37M	€33M
Y3	€5.95B	7.61%	€452M	€338M	€296M	€42M	€34M
Y4	€6.39B	7.64%	€488M	€365M	€319M	€46M	€36M
Y5	€6.87B	7.68%	€528M	€394M	€342M	€52M	€38M
Y6	€7.39B	7.71%	€570M	€425M	€344M	€82M	€56M
Y7	€7.94B	7.75%	€615M	€459M	€369M	€90M	€58M
Y8	€8.42B	7.75%	€652M	€486M	€318M	€169M	€102M
Y9	€8.80B	7.75%	€682M	€508M	€252M	€256M	€145M
Y10	€9.06B	7.75%	€702M	€523M	€176M	€347M	€184M

Methodology & flags

Damodaran FCFF DCF, 10y explicit + perpetuity. Country risk premium derived from a 45-country revenue-weighted mix (US 18.5% / DE 11% / China 9% / UK 6% / France 5% top-five — EMEA-heavy with EM tail) crossed with Damodaran 2026 CRPs, landing at 1.15%. Synthetic credit rating A3/A- from interest coverage and €1.79B book debt vs €2.04B book equity. Monte Carlo: 1000 iterations sampling revenue growth, target margin, terminal growth and governance discount with council-revised downside-widened bands (margin low 6.0% prices the JPM Chinese-disintermediation thesis materialising). Council-revised inputs: target_op_margin 7.75% (was 8.5%) anchored on Brenntag Specialties peer not Retail Distributors median; sales_to_capital_y6_10 1.5 (was 1.8) because €2.61B goodwill base is not capital-light; governance_discount 8% (was 5%) on management-transition signal. Full pressure-test in council/council-report-2026-05-24.html. Engine v1.0.0 · result: /Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/imcd/output/2026-05-25-result.json

R&D cap: OFF · Lease cap: OFF · Failure: OFF · ESO: OFF
Governance haircut: 8% (pre €62.87 → post €57.84) — council-revised UP from 0.05; three reviewers flagged the original as treating diffuse ownership as the only consideration. CEO/CFO churn + dividend cut + first-since-IPO equity raise reads as "management reacting, not steering."
Cost-of-debt: synthetic A3/A- (default spread 89bp over EUR rf)
Sensitivity tornado: not run · superseded by 1000-iter Monte Carlo (rev growth · target margin · terminal_g · governance)

Damodaran FCFF DCF · dark theme. Generated 2026-05-25T00:49:23 from /Users/valentin/Documents/notes_jiliac_labs/Finance/Damodaran/valuations/imcd/output/2026-05-25-result.json.